Angina Pectoris Drugs Market Report 2025

The angina pectoris drugs market size has grown strongly in recent years. It will grow from $12.32 billion in 2024 to $12.94 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to the high prevalence of cardiovascular diseases, aging population demographics, lifestyle factors, increase in hypertension rates, and diabetes prevalence.

The angina pectoris drugs market size is expected to see strong growth in the next few years. It will grow to $16.55 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising global obesity rates, advancements in precision medicine, focus on preventive cardiology, patient education initiatives, and research on novel therapeutic targets. Major trends in the forecast period include telemedicine for remote monitoring, real-world evidence and outcome studies, patient-centric medication education, strategic alliances for market access, regulatory advances, and expedited approvals.

The rising prevalence of cardiovascular diseases is expected to drive the growth of the angina pectoris drug market in the coming years. Cardiovascular diseases include a variety of disorders that affect the heart and blood vessels, such as coronary artery disease, high blood pressure, heart failure, and stroke. This increase in cardiovascular diseases (CVD) can be linked to several factors, including an aging population, unhealthy lifestyles, and the obesity epidemic. Medications for angina pectoris, such as nitrates, beta-blockers, and calcium channel blockers, are effective in relieving chest pain and discomfort resulting from inadequate blood flow to the heart, thus improving patients' overall quality of life. For instance, data released by the British Heart Foundation, a UK-based cardiovascular research charity, in September 2024, indicated that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including about 4 million males and 3.6 million females. These diseases account for around 27% of all deaths in the UK, resulting in over 170,000 deaths annually, or about 480 deaths per day, which translates to one death every three minutes. Therefore, the increasing prevalence of cardiovascular diseases is fueling the growth of the angina pectoris drug market.

The burgeoning rates of hypertension and diabetes are projected to stimulate the expansion of the angina pectoris drug market in the foreseeable future. Hypertension, characterized by high arterial blood pressure, and diabetes, a long-term condition marked by elevated blood glucose levels, are common risk factors for cardiovascular ailments such as angina pectoris. The surge in the occurrence of these conditions amplifies the demand for medications used in angina treatment. For instance, data from the World Health Organization in June 2022 reported over 2.5 million recorded cases of hypertension across more than 15,000 healthcare facilities by April 2022. Similarly, information from the Australian Institute of Health and Welfare in June 2023 highlighted that the number of Australians affected by diabetes had surged approximately 2.8 times in the past decade, escalating from 460,000 to 1.3 million individuals. Therefore, the escalating rates of hypertension and diabetes significantly contribute to driving the angina pectoris drug market.

A prominent trend in the angina pectoris drugs market involves a focus on product innovation, with major companies within the industry leveraging new technologies to maintain their market positions. Notably, in March 2023, Hikma Pharmaceuticals plc, a UK-based firm, introduced the Labetalol Hydrochloride Injection, USP, in a prefilled syringe, which received approval from the US Food and Drug Administration (FDA). This particular product, available in hospitals in a 10 mg/2 mL PFS format, serves the purpose of treating severe hypertension and reducing blood pressure.

The key players in the angina pectoris drug market are strategically pursuing approvals for innovative products, such as the FDA's authorization of Nitrostat (Nitroglycerin Sublingual Tablets) for managing angina, aiming to better cater to their existing consumer base. Nitrostat, sanctioned by the FDA for immediate angina treatment or acute prevention, witnessed approval for sale in various strengths (0.3 mg, 0.4 mg, and 0.6 mg) in March 2022, announced by Zydus Lifesciences Ltd., an India-based pharmaceutical company. These sublingual tablets are prescribed for patients with coronary artery disease (CAD) to alleviate angina or chest discomfort, even aiding in preventing soreness before physical activity. Nitroglycerin, a part of the nitrate drug class, functions by dilating and relaxing blood vessels, thus facilitating improved blood circulation to the heart.

In November 2022, Alcon, a US-based pharmaceutical and medical device company, completed the acquisition of Aerie Pharmaceuticals Inc., a move that significantly expands Alcon's commercial product range and development pipeline. Aerie Pharmaceuticals, Inc., a US-based clinical-stage pharmaceutical firm, contributes to the angina pectoris drug market, adding depth and diversity to Alcon's portfolio, particularly in the realm of ophthalmic pharmaceuticals.

Major companies operating in the angina pectoris drugs market include Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AERIE PHARMACEUTICALS INC., AbbVie Inc., Amgen Inc., Gilead Sciences Inc., GlaxoSmithKline plc, H. Lundbeck A/S, Ipsen S.A., Lupin Pharmaceuticals Inc., Merck KGaA, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A.

North America was the largest region in the angina pectoris drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the angina pectoris drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Angina pectoris medications are employed to address the symptoms of angina pectoris, a condition characterized by chest pain or discomfort resulting from inadequate blood and oxygen supply to a portion of the heart. These drugs aim to alleviate the chest pain associated with coronary heart disease.

The primary categories of angina pectoris medications encompass nitrates, antiplatelet agents, beta-adrenergic blockers, calcium channel blockers, anti-ischemic agents, statins, antihypertensive agents, and other pharmaceuticals. Among these, nitrates and nitrites, containing nitrogen and oxygen atoms, play a significant role in managing angina pectoris, a condition marked by chest pain due to reduced blood flow to the heart. Their usage extends to treating stable angina, unstable angina, and Prinzmetal's angina. These medications are delivered through oral, parenteral, transdermal, and various other administration routes utilized in hospitals, homecare settings, specialty clinics, and other end-user contexts.

The angina pectoris drugs market research report is one of a series of new reports that provides angina pectoris drugs market statistics, including angina pectoris drugs industry global market size, regional shares, competitors with an angina pectoris drugs market share, detailed angina pectoris drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the angina pectoris drugs industry. This angina pectoris drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The angina pectoris drugs market consists of sales of aspirin, ranolazine, and angiotensin-converting enzyme inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.